Search Results for "Pharmac Cost Of Sativex In New Zealand"

18:12 EDT 28th March 2015 | BioPortfolio

Matching Channels

Marginal cost

TASH Biotechnology

Shanghai TASH Biotechnology Co.,Ltd. specializes in peptide development on the basis of high technology. TASH Biotechnology are focusing on custom peptide synthesis, and the research, development...


BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...


CombiCult® is an award winning, combinatorial screening technology that allows scientists to discover new and improved stem cell differentiation protocols. How Combicult® works A short o...

Latin America

Latin America encompasses the Caribbean, South America and Central America. These countries are important players in the biotechnology industry, not only as consumers, but as contributors. The env...

Matching News

New Zealand’s PHARMAC calls for information on anti-diabetic agents

New Zealand’s Pharmaceutical Management Agency, PHARMAC, today revealed it is interested in receiving…

PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards (DHBs) over the next five years, says PHARMAC, New Zealand’s Pharmaceutical Management Agency...

PHARMAC in negotiations over rare disorders medicines

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is in active negotiations with several suppliers…

PHARMAC Stressing Biosimilar Use For Savings

In its annual review, the New Zealand pharmaceutical management agency PHARMAC says it has made substantial savings from switching to generics and is also now emphasizing the use of biosimilars.

New Zealand proposal for sole supply of Remicade in DHB hospitals

Following a Request for Tender for infliximab issued on September 2, 2014 (RFT), New Zealand’s Pharmaceutical Management Agency, PHARMAC, is seeking feedback.

PHARMAC’s Largest Single Deal Sees Nine Novartis Drugs Funded

PHARMAC, New Zealand’s pharmaceutical management agency, signed agreements with Novartis and Biogen Idec in mid-October that sees 10 new medicines funded at reduced prices, or wider access to eight ...

Bayer’s Jadelle to be listed in New Zealand

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with Bayer New Zealand, the local subsidiary of German pharma major Bayer (BAYN: DE) for the listing...

Savings from extended role exceed NZ$100 million, says NZ’s PHARMAC

District Health Boards are poised to save more than $100 million over five years as a result of New Zealand’s Pharmaceutical Management Agency PHARMAC’s expanded role, the agency reports in its An...

Matching PubMed Articles

Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.

Objective Spending on medicines under the Pharmaceutical Benefits Scheme (PBS) represents the ninth largest expense to the Federal Government. A recent report by the Commission of Audit to the Federal...

Assessment of the effectiveness and safety of Sativex ® in compassionate use.

INTRODUCTION. Sativex ® is a drug approved for use in the treatment of spasticity in multiple sclerosis. We sought to study the tolerability and effectiveness of this drug product in pathologies beyo...

A cost-benefit analysis of pre- and post-lambing anthelmintic treatments to twin-bearing ewes on commercial farms in the southern North Island of New Zealand.

Abstract AIM: To conduct a cost-benefit analysis of the administration of anthelmintics to adult ewes around lambing.

Opioid substitution treatment in New Zealand: a 40 year perspective.

We provide an overview of the history and philosophy of the treatment for opioid dependence, which has been dominated by methadone substitution treatment for the past 40 years in New Zealand. Although...

Cost of traumatic brain injury in New Zealand: Evidence from a population-based study.

We aimed to estimate from a societal perspective the 1-year and lifetime direct and indirect costs of traumatic brain injury (TBI) for New Zealand (NZ) in 2010 projected to 2020.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement